MedTrace Logo

Drug-drug Interaction Study Between UIC201603, and UIC201604

NCT06568133 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2024-08-23

No results posted yet for this study

Summary

An open-label, multiple-dosing, two-arms, one-sequence study to evaluate the safety and pharmacokinetics after co-administration of UIC201603 and UIC201604 in healthy volunteers

Conditions

  • Healthy

Interventions

DRUG

UIC201603 and co-administration of UIC201603 and UIC201604

* UIC201603 2 Caps/day for 7 days * Wash out 7 days * UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 days

DRUG

UIC201604 and co-administration of UIC201603 and UIC201604

* UIC201604 1 Tabs/day for 7 days * Wash out 7 days * UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 daysadministration of UIC201603 and UIC201604

Sponsors & Collaborators

  • Korea United Pharm. Inc.

    lead INDUSTRY

Principal Investigators

  • Janghee Hong, M.D.,Ph.D · Chungnam National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-15
Primary Completion
2017-07-04
Completion
2018-02-07

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06568133 on ClinicalTrials.gov